Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521807 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| SCHEMBL19472343 | 0.88 | ALDH1A1 (0.52) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL8470037 | 0.88 | ALOX15 (0.66) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL30064486 | 0.88 | ALOX15 (0.66) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL27888379 | 0.88 | ALOX15 (0.66) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| SCHEMBL16590765 | 0.88 | ALDH1A1 (0.54) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL167562 | 0.88 | ALOX15 (0.66) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL34004 | 0.88 | ALOX15 (0.66) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL29350486 | 0.88 | ALOX15 (0.66) | ALDH1A1SLC7A5LCKPTGS2ALOX15 | |
| Melevodopa SCHEMBL17747950 | 0.86 | ALOX15 (0.64) | ALDH1A1SLC7A5LCKPTGS2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427737-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NeuroVive Pharmaceutical AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| EP-2654753-B1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| EP-2691413-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | Neurovive Pharmaceutical AB (SE) | 2014-02-05 | — | — | EP | disclosed |
| EP-2654753-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | Neurovive Pharmaceutical AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085553-A1 | SANGLIFEHRIN DERIVATIVES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | ALDH1A1 2007/4885SLC7A5 1425/4885LCK 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.